Symbols

CERS

Cerus·NASDAQ

--(--)

CERS fundamentals

CERS Q4 2025 Earnings

Cerus (CERS) released its earnings on Mar 2, 2026: revenue was 64.60M (YoY +13.83%), beat estimates; EPS was -0.01 (YoY 0.00%), missed estimates.

Revenue / YoY

64.60M

+13.83%

EPS / YoY

-0.01

0.00%

Report date

Mar 2, 2026

CERS Earnings Call Summary for Q4,2025

Record Revenue Growth: 2025 total revenue $233.8M (+16% YoY), driven by U.S. platelets and EMEA expansion.
Strategic Partnerships: BCA agreement targets 30% U.S. market penetration; Germany's $30M platelet opportunity via INITIATE study.
IFC Acceleration: 80% revenue growth to $16.7M, shifting to 100% kit sales by 2026.
Financial Health: Positive non-GAAP EBITDA ($9.5M annual), but gross margin pressured by tariffs.
RBC Regulatory Progress: European CE Mark expected 2027; U.S. Phase III study results Q4 2026.

Earnings

EPS

Revenue

Revenue & Expenses

CERS has released its 2025 Q4 earnings report, with revenue of 64.58M, reflecting a YoY change of 13.79%, and net profit of -2.18M, showing a YoY change of 14.75%. The Sankey diagram below clearly presents CERS's revenue sources and cost distribution.

Key Indicators

Cerus (CERS) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Cerus (CERS)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Cerus (CERS)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Cerus (CERS)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown